BACKGROUND: Cytopenia occurs frequently during cytotoxic chemotherapy. Little is known about the optimal timing of influenza vaccination for patients receiving chemotherapy. This study compared the immunogenicity of an influenza vaccine administered concurrently with chemotherapy (day 1) and within the cytopenic period (day 11) during 3-week cytotoxic chemotherapy cycles. METHODS:Adult patients with solid cancer undergoing scheduled 3-weekcytotoxic chemotherapy were randomly assigned to receive the 2014-2015 seasonal influenza vaccine on day 1 or 11 during the chemotherapy cycle. Patients were stratified by their age (<60 and ≥60 years) and previous influenza vaccination status. Antibody responses to influenza vaccine strains H1N1, H3N2, and B were measured before and 21 to 28 days after vaccination with a hemagglutination inhibition antibody assay. RESULTS:Ninety-seven patients were randomized into a day 1 group (n = 43) or a day 11 group (n = 54). Eighty-three patients were included in the final analysis. The mean age was 54 (± 11) years. Cancer types included breast (61%) and lung cancer (30%). Baseline characteristics were not significantly different between the groups. Seroprotection rates after vaccination were also not significantly different for the day 1 and 11 groups (strain H1N1, 67% vs 75% [P = .403]; strain H3N2, 77% vs 80% [P = .772]; strain B, 21% vs 27% [P = .472]). Seroconversion rates and postvaccinationgeometric mean titers were also similar for the groups. Vaccine-related adverse events were more common in the day 11 group (13% vs. 32%; P = .040). CONCLUSIONS: The antibody responses to influenza vaccination on days 1 and 11 during a 3-week cytotoxic chemotherapy cycle were comparable. Influenza vaccination can be performed concurrently with cytotoxic chemotherapy or during the cytopenic period. Cancer 2017;123:841-48.
RCT Entities:
BACKGROUND:Cytopenia occurs frequently during cytotoxic chemotherapy. Little is known about the optimal timing of influenza vaccination for patients receiving chemotherapy. This study compared the immunogenicity of an influenza vaccine administered concurrently with chemotherapy (day 1) and within the cytopenic period (day 11) during 3-week cytotoxic chemotherapy cycles. METHODS: Adult patients with solid cancer undergoing scheduled 3-week cytotoxic chemotherapy were randomly assigned to receive the 2014-2015 seasonal influenza vaccine on day 1 or 11 during the chemotherapy cycle. Patients were stratified by their age (<60 and ≥60 years) and previous influenza vaccination status. Antibody responses to influenza vaccine strains H1N1, H3N2, and B were measured before and 21 to 28 days after vaccination with a hemagglutination inhibition antibody assay. RESULTS: Ninety-seven patients were randomized into a day 1 group (n = 43) or a day 11 group (n = 54). Eighty-three patients were included in the final analysis. The mean age was 54 (± 11) years. Cancer types included breast (61%) and lung cancer (30%). Baseline characteristics were not significantly different between the groups. Seroprotection rates after vaccination were also not significantly different for the day 1 and 11 groups (strain H1N1, 67% vs 75% [P = .403]; strain H3N2, 77% vs 80% [P = .772]; strain B, 21% vs 27% [P = .472]). Seroconversion rates and postvaccination geometric mean titers were also similar for the groups. Vaccine-related adverse events were more common in the day 11 group (13% vs. 32%; P = .040). CONCLUSIONS: The antibody responses to influenza vaccination on days 1 and 11 during a 3-week cytotoxic chemotherapy cycle were comparable. Influenza vaccination can be performed concurrently with cytotoxic chemotherapy or during the cytopenic period. Cancer 2017;123:841-48.
Authors: Aaron Shengting Mai; Ainsley Ryan Yan Bin Lee; Ryan Yong Kiat Tay; Lauren Shapiro; Astha Thakkar; Balazs Halmos; Albert Grinshpun; Yair Herishanu; Ohad Benjamini; Tamar Tadmor; Rachna T Shroff; Bonnie J LaFleur; Deepta Bhattacharya; Siyu Peng; Jeremy Tey; Soo Chin Lee; Louis Yi Ann Chai; Yu Yang Soon; Raghav Sundar; Matilda Xinwei Lee Journal: Eur J Cancer Date: 2022-06-03 Impact factor: 10.002
Authors: C T Rieger; B Liss; S Mellinghoff; D Buchheidt; O A Cornely; G Egerer; W J Heinz; M Hentrich; G Maschmeyer; K Mayer; M Sandherr; G Silling; A Ullmann; M J G T Vehreschild; M von Lilienfeld-Toal; H H Wolf; N Lehners Journal: Ann Oncol Date: 2018-06-01 Impact factor: 32.976
Authors: David Tougeron; Barbara Seitz-Polski; Maxime Hentzien; Firouze Bani-Sadr; Jean Bourhis; Michel Ducreux; Sébastien Gaujoux; Philippe Gorphe; Boris Guiu; Anne Claire Hardy-Bessard; Khê Hoang Xuan; Florence Huguet; Thierry Lecomte; Astrid Lièvre; Christophe Louvet; Léon Maggiori; Pascale Mariani; Pierre Michel; Amélie Servettaz; Juliette Thariat; Virginie Westeel; Thomas Aparicio; Jean Yves Blay; Olivier Bouché Journal: Bull Cancer Date: 2021-04-12 Impact factor: 1.276
Authors: Aakash Desai; Justin F Gainor; Aparna Hegde; Alison M Schram; Giuseppe Curigliano; Sumanta Pal; Stephen V Liu; Balazs Halmos; Roman Groisberg; Enrique Grande; Tomislav Dragovich; Marc Matrana; Neeraj Agarwal; Sant Chawla; Shumei Kato; Gilberto Morgan; Pashtoon M Kasi; Benjamin Solomon; Herbert H Loong; Haeseong Park; Toni K Choueiri; Ishwaria M Subbiah; Naveen Pemmaraju; Vivek Subbiah Journal: Nat Rev Clin Oncol Date: 2021-03-15 Impact factor: 66.675